BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Blackfield Announces Fourth Major Pharmaceutical Company Collaboration


7/9/2013 9:44:06 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Cologne, Germany, July 9, 2013 / B3C newswire / - Blackfield announced today that it has entered a collaboration with AstraZeneca, a global biopharmaceutical company. Under the terms of the agreement, Blackfield will apply its genomics technologies and computational biology capabilities to validate preclinical models in support of one of AstraZeneca’s oncology drug development programs. The collaboration with AstraZeneca marks Blackfield’s fourth partnership with a major pharmaceutical company within one year of starting up. Earlier this year Blackfield entered service agreements with Janssen Pharmaceuticals, Inc. (a division of Johnson & Johnson), Merck KGaA and Boehringer Ingelheim. Professor Roman Thomas, Blackfield’s Scientific Director said: “We are pleased to help AstraZeneca make more informed decisions in the clinical stage of their compound development. By applying our unique background in genomics, cancer medicine, and computational biology, Blackfield mines genomic information to support our clients in developing targeted cancer therapies. We are delighted that Blackfield’s position as a preferred scientific partner for global pharma companies has been confirmed this quickly. It demonstrates that our science-driven partnering approach that leverages genome analysis and oncology experience to offer expertise from one source is of highest value to the pharmaceutical industry.”

About Blackfield

Blackfield is a Germany-based company that was founded by renowned cancer researchers Axel Ullrich and Roman Thomas. Professor Thomas heads the Department of Translational Genomics at the University of Cologne. His lab strives to identify, characterize and validate novel targets for therapy in cancer and to develop novel technology for cancer genome diagnostics. Blackfield offers a broad spectrum of genomics and sequencing-based technologies; the main product is a customizable multigene assay to test tumor samples for genome alterations (mutations, insertions/deletions, amplifications, rearrangements) in more than 300 cancer-relevant genes, thus supporting patient stratification and response prediction. With all its services, Blackfield offers outstanding computational biology expertise and technology to support the analysis and interpretation of genomics datasets. Blackfield’s business model is highly flexible and centered on customized collaborations to find optimized solutions that transfer the latest scientific findings and target specific know-how from the lab to the clinic.

Contact:

Dr. Jutta Fritz

Blackfield AG

Email: info@blackfield.de

Phone: +49 221 / 88 82 38-15

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES